Document is current
Any future updates will be listed below
-
Authors
,
Amen, Alexandra M.
Barry, Kerrie W.
Boyle, John M.
Brook, Cara E.
Choo, Seunga
Cornmesser, L. T.
Dilworth, David J.
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
Ehrenberg, Alexander J.
Fedrigo, Indro
Friedline, Skyler E.
Graham, Thomas G. W.
Green, Ralph
Hamilton, Jennifer R.
Hirsh, Ariana
Hochstrasser, Megan L.
Hockemeyer, Dirk
Krishnappa, Netravathi
Lari, Azra
Li, Hanqin
Lin-Shiao, Enrique
Lu, Tianlin
Lyons, Elijah F.
Mark, Kevin G.
Martell, Lisa Argento
Martins, A. Raquel O.
McDevitt, Shana L.
Mitchell, Patrick S.
Moehle, Erica A.
Naca, Christine
Nandakumar, Divya
O’Brien, Elizabeth
Pappas, Derek J.
Pestal, Kathleen
Quach, Diana L.
Rubin, Benjamin E.
Sachdeva, Rohan
Stahl, Elizabeth C.
Syed, Abdullah Muhammad
Tan, I-Li
Tollner, Amy L.
Tsuchida, Connor A.
Tsui, C. Kimberly
Turkalo, Timothy K.
Urnov, Fyodor D.
Warf, M. Bryan
Whitney, Oscar N.
Witkowsky, Lea B.
- License Information
-
More Information
Article History
First Online: 18 June 2020
Competing interests
: The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences and Inari. J.A.D. is a director at Johnson & Johnson and has research projects sponsored by Biogen, Pfizer, AppleTree Partners and Roche.
Free to read: This content has been made available to all.
